Detalles de la búsqueda
1.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36273926
2.
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(5): 710-722, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32359490
3.
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecol Oncol
; 159(1): 101-111, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32861537
4.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 390(10106): 1949-1961, 2017 Oct 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28916367
5.
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
J Clin Oncol
; 38(30): 3494-3505, 2020 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32840418
Resultados
1 -
5
de 5
1
Próxima >
>>